Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...

Nearly 12 months later, green shoots may finally be appearing following a desperately dark time for the German group that invented aspirin ... Bayer’s ability to profit off the drug.

For decades, taking low-dose aspirin every day was widely recommended as an easy way to prevent heart attacks and strokes. But that advice has changed.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As low-dose prophylactic aspirin therapy becomes common among older people, potential risks that are associated with such treatment assume increasing importance. In particular, some clinicians are ...

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...